The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy

Bartalena, Luigi; J. Kahaly, George; Baldeschi, L.; Dayan, Colin; Eckstein, Anja; Marcocci, C; Marinò, Michele; Vaidya, Bijay; M. Wiersinga, Wilmar; _, _; _, _; Ayvaz, Göksün; Konuk, Onur; Ćirić, Jasmina; Beleslin, Bijliana; Boschi, Antonella; Cristina Burlacu, Maria; Morris, Dan; Le Moli, Rosario; Marino, Antonio; McKee, Justin; Zammit, Nicola; Führer, Dagmar; Pereni, Ioana; Schittkowski, Michael; Raddatz, Dirk; Lee, Vickie; Meeran, Karim; Abeillon, J.; Soui Thcong, Thia; A. Ponto, Katharina; Muller, Ilaria; Currò, Nicola; Hintschich, Christoph; Gärtner, Roland; H. S. Pearce, Simon; Clarke, Lucy; Heiberg Brix, Thomas; Bechtold, Dorte; Rudovfsky, Gottfried; Fichter, N.; Pasquier, L.; Meney, J.; Menconi, Francesca; Lanzolla, Giulia; Sundar, Gangadhara; Peiling Yung, Samantha; Boboridis, Kostas; Anagnostis, Panagiotis; Pérez López, Marta; Javier Sanchez, Carlos; Laura Tanda, Maria; Donati, Simone; Papp, Andrea; Li, Shuren; Jabłońska, Anna; Miśkiewicz, Piotr; Juri, Jelena; Baretić, Maja

doi:10.1530/eje-21-0479

Public

The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy

Published in European Journal of Endocrinology • Jul 23, 2021

Authors:

Luigi Bartalena

George J. Kahaly

L. Baldeschi

Abstract

Graves' orbitopathy (GO) is the main extrathyroidal manifestation of Graves' disease (GD). Choice of treatment should be based on the assessment of clinical activity and severity of GO. Early referral to specialized centers is fundamental for most patients with GO. Risk factors include smoking, thyr...

Subject

Medicine

Prednisone

Azathioprine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!